Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00014-19. doi: 10.1128/AAC.00014-19. Print 2019 May.

Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Author information

1
Center for Emerging and Reemerging Infectious Diseases and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA smithra@u.washington.edu.
2
Center for Emerging and Reemerging Infectious Diseases and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
3
Service des Maladies Infectieuses et Tropicales, CHNU de Fann, Dakar, Senegal.
4
Department of Global Health, University of Washington, Seattle, Washington, USA.

Abstract

We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.

KEYWORDS:

HIV treatment; HIV-2; West Africa; antiretroviral therapy; bictegravir; drug resistance; human immunodeficiency virus; integrase

PMID:
30803972
PMCID:
PMC6496081
[Available on 2019-10-25]
DOI:
10.1128/AAC.00014-19

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center